Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
- 15 September 2014
- reference entry
- review article
- Published by Wiley
- Vol. 9 (9), CD011230
- https://doi.org/10.1002/14651858.cd011230.pub2
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the systemic safety of intravitreal bevacizumab compared with intravitreal ranibizumab in people with neovascular AMD.This publication has 60 references indexed in Scilit:
- Addressing Dichotomous Data for Participants Excluded from Trial Analysis: A Guide for Systematic ReviewersPLOS ONE, 2013
- A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus GoldstandardPLOS ONE, 2012
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisAnnals Of Oncology, 2012
- The estimated prevalence and incidence of late stage age related macular degeneration in the UKBritish Journal of Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabEye, 2011
- A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studiesJournal of Clinical Epidemiology, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Contradicted and Initially Stronger Effects in Highly Cited Clinical ResearchJama-Journal Of The American Medical Association, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003